This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dowen, S. E. Articles by Lemoine, N. R. Search for Related Content PubMed PubMed Citation Articles by Dowen, S. E. Articles by Lemoine, N. R.

(American Journal of Pathology. 2005;166:81-92.)
© 2005 American Society for Investigative Pathology

Expression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer

Sally E. Dowen^*, Tatjana Crnogorac-Jurcevic^*, Rathi Gangeswaran^*, Mikkel Hansen^*, Jyrki J. Eloranta^*, Vipul Bhakta^*, Teresa A. Brentnall, Jutta Lüttges, Gunther Klöppel and Nick R. Lemoine^*

From the Molecular Oncology Unit,^* Cancer Research UK, Barts and The London School of Medicine and Dentistry, John Vane Science Centre, London, United Kingdom; the University of Washington Medical Center, Seattle, Washington; and the Department of Pathology, University of Kiel, Kiel, Germany

S100P is a member of the S100 family of calcium-binding proteins and there have been several recent reports of its overexpression in pancreatic ductal adenocarcinoma (PDAC). We have used Far Western screening and in vitro interaction assays to identify and confirm a novel target protein for S100P. We have named this protein S100PBPR, and shown that its interaction with S100P is dependent on Ca²⁺ or Mg²⁺. S100PBPR was found to localize to cell nuclei where S100P is also present, and the two proteins co-immunoprecipitate. By in situ hybridization, S100PBPR transcript was found in islet cells but not duct cells of the healthy pancreas. Both S100P and S100PBPR were detected by quantitative real-time polymerase chain reaction in pancreatic intraepithelial neoplasia (PanIN) and PDAC samples, and in situ hybridization revealed the presence of S100PBPR transcript in malignant PDAC cells. These data suggest that an interaction between S100P and S100PBPR may be involved in early pancreatic cancer. S100P was further investigated in PanIN lesions and immunohistochemical analysis showed its expression to correlate significantly with increasing grade of PanINs, being found as early as PanIN-1 with more prevalent expression in PanIN-2 and -3. These data suggest that S100P can be added to the genetic progression model for PDAC.

This article has been cited by other articles:

				H. J. Whiteman, M. E. Weeks, S. E. Dowen, S. Barry, J. F. Timms, N. R. Lemoine, and T. Crnogorac-Jurcevic The Role of S100P in the Invasion of Pancreatic Cancer Cells Is Mediated through Cytoskeletal Changes and Regulation of Cathepsin D Cancer Res., September 15, 2007; 67(18): 8633 - 8642. [Abstract] [Full Text] [PDF]

				P. C. Mahon, P. Baril, V. Bhakta, C. Chelala, K. Caulee, T. Harada, and N. R. Lemoine S100A4 Contributes to the Suppression of BNIP3 Expression, Chemoresistance, and Inhibition of Apoptosis in Pancreatic Cancer Cancer Res., July 15, 2007; 67(14): 6786 - 6795. [Abstract] [Full Text] [PDF]

				K. Ohuchida, K. Mizumoto, T. Egami, H. Yamaguchi, K. Fujii, H. Konomi, E. Nagai, K. Yamaguchi, M. Tsuneyoshi, and M. Tanaka S100P Is an Early Developmental Marker of Pancreatic Carcinogenesis. Clin. Cancer Res., September 15, 2006; 12(18): 5411 - 5416. [Abstract] [Full Text] [PDF]

				T. Arumugam, D. M. Simeone, K. Van Golen, and C. D. Logsdon S100P Promotes Pancreatic Cancer Growth, Survival, and Invasion Clin. Cancer Res., August 1, 2005; 11(15): 5356 - 5364. [Abstract] [Full Text] [PDF]